ESSENTIAL VIEWING: KEY TRIALS FROM SABCS® 2025

Welcome Message

Overview

• Stay informed with daily video updates on the most significant science presented at SABCS® 2025.
   
• Watch top global experts review key presentations, featuring original slides in concise videos.
   
• Short, engaging videos for quick learning. 

Featuring

General and Rapid Fire Sessions on

• Predictive and Prognostic Biomarkers
• Early Breast Cancer
• Local Therapy
• Metastatic Breast Cancer
• Quality of Life/Survivorship
• Artificial Intelligence

RF1-01

Postoperative Complication Rates of Minimally Invasive Mastectomy Compared to Conventional Mastectomy: A Prospective Multicenter Cohort Study (MARRES)

Hyung Seok Park, Yonsei University College of Medicine, Seoul, Korea, Republic of

#local therapy

RF1-02

Surgical outcomesin the ALTERNATE trial (Alliance A011106) -a randomized phase 3 neoadjuvant endocrine therapy (NET) trial in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC)

Ann Marilyn Leitch, UT Southwestern Medical Center, Dallas, TX

#local therapy

RF1-03

Magnetic resonance imaging based internal mammary node response after neoadjuvant therapy to guide postoperative internal mammary node boost radiotherapy in breast cancer

Yushuo Peng, Peking University Cancer Hospital and Institute, Beijing, China

#local therapy

RF1-04

Early Adverse Symptoms Predict Response to Treatment Among Patients in the I-SPY Trial

Amrita Basu, University of California San Francisco, San Francisco, CA

#QOL Survivorship

RF1-05

Utilization of ePROs and smart pill bottles to improve adherence to adjuvant endocrine therapy in early-stage breast cancer

Steven A Manobianco, Sidney Kimmel Comprehensive Cancer Center – Jefferson Health, Philadelphia, PA

#QOL Survivorship

RF1-06

Discordance in End-of-Life Decision-Making: A Quantitative Study on the Values and Preferences of Japanese Cancer Patients and Their Family Members

Akihiko Ozaki, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan

#QOL Survivorship

RF1-07

Cruciferous vegetable intake, dietary glucosinolate and risk of breast cancer in 2 large prospective studies

Andrea Romanos-Nanclares, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

#QOL Survivorship

RF2-01

Prognostic Markers in Residual Tumors after neoadjuvant chemotherapy (NACT) for Early Triple-negative Breast Cancer (TNBC) – a Pooled Analysis from nine Neoadjuvant GBG/AGO-B Trials

Johannes Holtschmidt, GBG c/o GBG Forschungs GmbH, Neu Isenburg, Germany

RF2-02

Pooled analysis of the BrighTNess, CALGB 40603 (Alliance), and GeparSixto clinical trials identifies the impact of neoadjuvant carboplatin on pCR and survival in early-stage triple-negative breast cancer

Brooke M Felsheim, University of North Carolina at Chapel Hill, Chapel Hill, NC

#EBC

RF2-03

Adjuvant epirubicin plus cyclophosphamide followed by taxanes with or without carboplatin for early stage triple-negative breast cancer (RJBC 1501): a randomized controlled phase III trial

Xiaosong Chen, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

#EBC

RF2-04

Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high-risk early-stage triple-negative breast cancer (CITRINE): a phase 3 randomized trial

Zhi-Ming Shao, Fudan University Shanghai Cancer Center, Shanghai, China

#EBC

RF2-06

Impact of Immune Checkpoint Inhibition (CPI) on Fertility in Young Women with Early Triple-Negative Breast Cancer (TNBC) receiving neoadjuvant Chemotherapy (NACT): A Prospective Substudy of the NSABP B-59/GBG-96-GeparDouze Trial

Mattea Reinisch, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany

#QOL Survivorship

RF2-07

Nodal disease burden in patients with clinically node-positive breast cancer undergoing tailored axillary surgery with or without axillary dissection in the neoadjuvant and upfront surgery setting: pre-planned TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)

Walter P. Weber, University of Basel, Basel, Switzerland & Breast Clinic, University Hospital Basel, Basel, Switzerland

#local therapy

GS1-01

Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer

Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN

#MBC

GS1-02

Efficacy and safety of neoadjuvant trastuzumab deruxtecan versus standard of care chemotherapy plus trastuzumab plus pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV

Nadia Harbeck, LMU University Hospital, Munich, Germany

#EBC

GS1-03

Discussant for GS1-01 and GS1-02: Evolving landscape of her2+ breast cancer

Ciara C O'Sullivan, Mayo Clinic, Rochester, MN

GS1-04

Adjuvant aromatase inhibitor or tamoxifen in patients with hormone receptor-positive/HER2-positive early breast cancer: an exploratory analysisfrom the ALTTO (BIG 2-06) trial

Matteo Lambertini, University of Genova – IRCCS Ospedale Policlinico San Martino, Genoa, Italy

#EBC

GS1-05

Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the ECOG-ACRIN-1181/CompassHER2 pCR trial

Sunil S Badve, Emory School of Medicine, Atlanta, GA (Kevin Kalinsky?)

#Predictive and Prognostic biomarkers

GS1-06

Prognostic and predictive associations of manual, digital and AI-derived tumor infiltrating lymphocytes-scoring: A retrospective analysis from the Phase III APHINITY trial

Roberto Salgado, Peter MacCallum Cancer Centre, Melbourne, Australia

#AI

GS1-07

Circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2-positive (HER2[+]) Early Breast Cancer (EBC): Translational analysis of PHERGain neoadjuvant tailored treatment study

Antonio Llombart-Cussac, Hospital Arnau de Vilanova; Translational Oncology Group, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU; Medica Scientia Innovation Research (MedSIR), Valencia, Spain

#Predictive and Prognostic biomarkers

GS1-08

Discussant for GS1-05, GS1-06, GS1-07

Heather A Parsons, Fred Hutchinson Cancer Center, Seattle, WA

GS1-09

Multimodal Artificial Intelligence (AI) Models Integrating Image, Clinical, and Molecular Data for Predicting Early and Late Breast Cancer Recurrence in TAILORx

Joseph A Sparano, Icahn School of Medicine at Mount Sinai, New York, NY

#AI

GS1-10

Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+/HER2− (IHC 0, 1+, 2+/ISH−) metastatic breast cancer: Primary results from ASCENT-07

Komal L. Jhaveri, Memorial Sloan Kettering Cancer Center (MSKCC); Weill Cornell Medical College, New York, NY

#MBC

RF6-01

Associations Between Cardiac Radiation Dose Volume Metrics and Cardiac Specific Health Related Quality of Life for Patients with Breast Cancer Randomized to Proton versus Photon Radiation on the RadComp Trial

Jean L Wright, University of North Carolina, Chapel Hill, NC

RF6-02

Patient-reported outcomes (PROs) in DESTINY-Breast11: neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + anthracycline followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC)

Shanu Modi, Department of Medicine, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY

RF6-03

DESTINY-Breast11 (DB-11) safety: neoadjuvant trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + anthracycline followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC)

Giuseppe Curigliano, Division of Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS & Department of Oncology and Hematology-Oncology, University of Milano, Milano, Italy

RF6-04

Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with HER2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): patient-reported outcomes (PROs) from the DESTINY-Breast09 study

Mothaffar Rimawi, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX

ED6-01

Moving on up: ADCs in early-stage breast cancer

Sibylle Loibl, Goethe University of Frankfurt, Frankfurt, Germany

ED6-02

Positioning and sequencing of ADCs in metastatic breast cancer

Reshma L Mahtani, Baptist Health Miami Cancer Institute, Miami, FL

ED6-03

Activity of ADCs in patients with brain metastases

Andrew J Brenner, University of Texas Health Science Center at San Antonio, San Antonio, TX

RF3-01

Clinical outcomes of invasive lobular carcinoma (ILC) versus non-lobular breast cancer (NLC) assessed by expert pathologists, an artificial intelligence (AI) CDH1 classifier, and AI-derived tumor microenvironment (TME) biomarkers in TAILORx

Roberto Salgado, Peter MacCallum Cancer Centre, Melbourne, Australia

#AI

RF3-02

Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer (TNBC) for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial

Carsten Denkert, Philipps-University Marburg and University Hospital Marburg (UKGM), Marburg, Germany

#Predictive and Prognostic biomarkers

RF3-04

Tumor-informed circulating tumor DNA analysis to assess molecular residual disease for prognosis and prediction of benefit from palbociclib in the PALLAS trial

Heather A Parsons, Fred Hutchinson Cancer Center, Seattle, WA

#Predictive and Prognostic biomarkers

RF3-05

Tissue-free circulating tumour DNA detection in patients with early triple negative breast cancer from the c-TRAK-TN trial

Niamh Cunningham, Royal Marsden Hospital, London, United Kingdom

#Predictive and Prognostic biomarkers

RF3-06

Tumor infiltrating lymphocytes in post-NACT residual tumors in ECOG-ACRIN EA1131 – impact of intrinsic subtypes.

Sunil S Badve, Emory School of Medicine, Atlanta, GA

#Predictive and Prognostic biomarkers

RF3-07

A Multimodal-Multitask Deep Learning Model Trained in NSABP B-42 and Validated in TAILORx for Late Distant Recurrence Risk in HR+ Early Breast Cancer

Eleftherios Mamounas, National Surgical Adjuvant Breast and Bowel Project and AdventHealth Cancer Institute, Orlando, FL

#AI

GS2-01

More versus less invasive axillary surgical staging procedures in breast cancer patients converting from a clinically node-positive to a clinically node-negative stage through neoadjuvant chemotherapy – primary endpoint analysis of the international prospective multicenter AXSANA/EUBREAST 3(R)study

Thorsten Kühn, Die Filderklinik gGmbH / University of Ulm, Ulm, Germany

#local therapy

GS2-02

Axillary surgery in breast cancer patients with one to three sentinel node macrometastases and breast-conserving therapy: Secondary results of the INSEMA trial

Toralf Reimer, University of Rostock, Rostock, Germany

GS2-03

Insights of applied radiotherapy among patients undergoing breast-conserving surgery with or without axillary sentinel lymph node biopsy: secondary results from the INSEMA trial

Guido Hildebrandt, University Medicine Rostock, Rostock, Germany

#local therapy

GS2-04

Heating up cold tumors: single-cell mapping of immune and adenosine pathway reprogramming in luminal B breast cancer (Neo-CheckRay trial)

Marcela Carausu, Institut Jules Bordet, Brussels, Belgium

#Translational

GS2-05

Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer

Gaorav Gupta, University of North Carolina at Chapel Hill, Chapel Hill, NC

GS2-06

Discussant for GS2-05

Stephen Shiao

GS2-07

Effect of Preoperative Breast MRI Staging on Local Regional Recurrence (LRR) in Early Stage Breast cancer: Alliance A011104/ACRIN 6694

Isabelle Bedrosian, University of Texas MD Anderson Cancer Center, Houston, TX

#local therapy

GS2-08

Discussant for GS2-07

Bruce Mann, Royal Melbourne Hospital, Melbourne, Australia

GS2-09

The single-arm confirmatory trial of tamoxifen alone without surgery for low-risk DCIS of the breast with ER-positive HER2-negative (LORETTA trial: JCOG1505)

Hiroji Iwata, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

#local therapy

GS2-10

Discussant for GS2-09

Eric P. Winer, Yale Cancer Center, New Haven, CT

GS2-11

Omission of sentinel lymph node biopsy in clinically T1-2 node-negative breast cancer patients treated with breast-conserving therapy: results of the Dutch BOOG 2013-08 randomized controlled trial after a median follow-up of 5 years

M. L. Smidt, Maastricht University Medical Center+, Maastricht, Netherlands

GS2-12

Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): final 10-year analysis of a randomised, factorial, multicentre, open-label, phase 3 study

Boon H Chua, University of New South Wales, Sydney, Australia

#local therapy

RF7-03

Updated results and an exploratory analysis of ESR1m circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC)

François-Clément Bidard, Institut Curie, Paris, France

RF7-04

Gedatolisib, a multi-target PI3K/AKT/mTOR (PAM) inhibitor, plus fulvestrant with or without palbociclib for second-line (2L) treatment of patients with HR+/HER2-/PIK3CA-wild type (WT) advanced breast cancer (ABC): updated results from the randomized, phase 3 VIKTORIA-1 trial

Barbara Pistilli, Gustave Roussy, Villejuif, France

RF7-05

Capivasertib plus fulvestrant in hormone receptor-positive (HR+) advanced breast cancer (ABC): exploratory ctDNA analyses from the Phase 3 CAPItello-291 trial

Nicholas C Turner, Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom

RF7-06

Primary results of Ambre, a randomized phase 3comparing mono-chemotherapy (ct) vs abemaciclib + endocrine therapy (et) in hr+/her2- advanced breast cancer (abc) with high visceral tumor burden

Véronique Dieras, Centre Eugène Marquis, Rennes, France

RF7-07

Adjuvant Palbociclib for ER+ Breast Cancer in the PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): Post-Recurrence Treatment and Overall Survival

Angela DeMichele, University of Pennsylvania, Philadelphia, PA

2025 FDA Approvals for HR+ Metastatic Breast Cancer

Melanie Royce

2025 FDA Approvals for HR+ Metastatic Breast Cancer

Maria Garcia-Jimenez

RF4-01

Central Nervous System Outcomes from the Phase III PATINA Trial (AFT-38)

Otto Metzger, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

#MBC

RF4-02

Efficacy Analysis of the Randomized Phase III DETECT V trial: Treatment De-escalation by Omission of Chemotherapy and the Effect of Adding Ribociclib in HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer

Wolfgang Janni, University Hospital Ulm, Ulm, Germany

#MBC

RF4-03

Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with high-risk human epidermal growth factor receptor 2-positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05

Sibylle Loibl, GBG Neu-Isenburg and Goethe University, Neu-Isenburg, Germany

RF4-04

Mechanisms of resistance to capivasertib in combination with CDK4/6 inhibitor (CDK4/6i) plus fulvestrant in patients with hormone receptor-positive/HER2-negative (HR+/HER2−) advanced breast cancer (ABC): exploratory analysis from the Phase 1b CAPItello-292 study

Dhivya Raja Sudhan, AstraZeneca, Gaithersburg, MD

#Predictive and Prognostic biomarkers

RF4-05

PIK3R1 (p85α) alterations define a targetable subset of breast cancer with broad sensitivity to PI3K and AKT inhibitors

Shalinda Fernando, NYU Langone, New York, NY

#Translational

RF4-06

FDG-PET/CT to assess therapeutic response in patients with bone-dominant metastatic breast cancer, FEATURE: ECOG-ACRIN EA1183

Jennifer M Specht, University of Washington/Fred Hutch Cancer Center, Seattle, WA

#MBC

RF4-07

Genomic characteristics of de novo HER2-positive metastatic breast cancer

Shu Yazaki, Memorial Sloan Kettering Cancer Center, New York, NY

#Translational

GS3-01

Menopausal Hormone Therapy and the Risk of Breast Cancer in Women with a Pathogenic Variant in BRCA1 or BRCA2

Joanne Kotsopoulos, Women's College Hospital, Toronto, ON, Canada

#QOL Survivorship

GS3-02

Fertility and ovarian function preservation in premenopausal women with early breast cancer: results from the multicenter prospective PREgnancy and FERtility (PREFER) study

Matteo Lambertini, University of Genova – IRCCS Ospedale Policlinico San Martino, Genoa, Italy

#QOL Survivorship

GS3-04

Effects of Acupuncture vs Sham Acupuncture and Usual Care on Cancer-Related Cognitive Difficulties Among Breast Cancer Survivors: The ENHANCE Randomized Clinical Trial

Jun Mao, Memorial Sloan Kettering Cancer Center, New York, NY

#QOL Survivorship

GS3-05

Evaluation of the Sensitivity to Endocrine Therapy (SETER/PR) assay to predict benefit from extended endocrine therapy in the NRG/NSABP B-42 trial

Eleftherios P Mamounas, AdventHealth Cancer Institute, Orlando, FL

#Predictive and Prognostic biomarker

GS3-06

Rb Functions as a Transcriptional Activator of ER Targets Following CDK4/6 Inhibition in Luminal Breast Cancer

April C Watt, Peter MacCallum Cancer Centre, Melbourne, Australia

#Translational

GS3-07

Risk-based breast cancer screening is safe, preferred by women and identifies highest risk individuals: Results from WISDOM 1.0

Laura J Esserman, UCSF, San Francisco, CA

#Prevention/Risk/Genetics

GS3-08

Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Updated efficacy results from the phase 3 EMBER-3 trial

Komal L Jhaveri, Memorial Sloan Kettering Cancer Center, New York, NY

#MBC

GS3-09

Clinical and biomarker subgroup analysis of evERA Breast Cancer: A Phase III trial of giredestrant plus everolimus in patients with estrogen receptor-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor

Hope S Rugo, City of Hope Comprehensive Cancer Center, Duarte, CA

#MBC

GS3-10

Expanding Therapeutic Options in Hormone Receptor Positive Metastatic Breast Cancer

Nicholas Turner, Institute of Cancer Research, London, United Kingdom

RF5-01

Cancer-specific risks associated with germline PALB2 pathogenic variants from a large clinical genetic testing cohort

Yen Y. Tan, Medical University of Vienna, Vienna, Austria

#Prevention/Risk/Genetics

RF5-02

Tbcrc 056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts

Erica L Mayer, Dana-Farber Cancer Institute, Boston, MA

#EBC

RF5-03

Olympian: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with brca mutations and early-stage her2-negative breast cancer

Nadine Tung, Beth Israel Deaconess Medical Center, Dana-Farber Harvard Cancer Center, Boston, MA

#EBC

RF5-04

Germline pathogenic variants in the personalized screening arm of the WISDOM Study: Findings from 23,098 women with no personal history of breast cancer

Kirkpatrick B. Fergus, University of California San Francisco, San Francisco, CA

#Prevention/Risk/Genetic

RF5-05

Predicting olaparib sensitivity in patients with metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations according to their homologous recombination status by the RAD51 test: Primary analysis of the RADIOLA phase II trial

Isabel Pimentel, Vall d’Hebron University Hospital / Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

#Predictive and Prognostic biomarkers

RF5-06

Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788: Results from the I-SPY2.2 trial

Paula R Pohlmann, University of Texas MD Anderson Cancer Center, Houston, TX

#EBC

SS5-01

Basic

Steffi Oesterreich, University of Pittsburgh School of Medicine, Pittsburgh, PA

SS5-02

Translational

Frederick M Howard, UChicago Medicine, Chicago, IL

SS5-03

Early Breast Cancer

William Gradishar, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

SS5-04

Metastatic Breast Cancer

Sonya A. Reid, Vanderbilt University Medical Center, Nashville, TN

Surgical Oncology

Judy C Boughey, Mayo Clinic, Rochester, MN

Radiation Oncology

Jonathan Strauss, Feinberg School of Medicine, Chicago, IL

Medical Oncology

Lajos Pusztai

Advocate

Julia Maues